Squibb supports MR contrast effort

Article

Advanced Magnetics of Cambridge, MA, picked up a hefty endorsementfor its magnetic resonance contrast technology this month withthe licensing of development, manufacturing and marketing rightsfor two MRI agents to Squibb Diagnostics, a division of

Advanced Magnetics of Cambridge, MA, picked up a hefty endorsementfor its magnetic resonance contrast technology this month withthe licensing of development, manufacturing and marketing rightsfor two MRI agents to Squibb Diagnostics, a division of Bristol-MyersSquibb. The agents involved are:

  • AMI-HS, a hepatocyte-specific agent for imaging livertumors; and

  • AMI-227, a blood-flow agent with potential applicationsin the imaging of lymph nodes and bone marrow.

Both agents are in preclinical development, according to JeromeGoldstein, Advanced Magnetics president and CEO. Squibb will beresponsible for filing investigational new drug applications forthe agents with the Food and Drug Administration.

Squibb will have marketing rights for both agents in all areasof the world except Europe, Brazil and Japan. Advanced Magneticshas already licensed rights to commercialize all of its MRI agentsto Guerbet in Europe and Brazil and Eiken Chemical in Japan.

The contrast developer is keeping options open for commercializationof agents in its home market. A North American licensing dealwas signed last year with Mallinckrodt for AMI 121, a gastrointestinalagent (SCAN 8/1/90).

Feridex, Advanced Magnetics' first magnetic particle MRI agenttargeted at liver cancer, is not yet licensed in the U.S. Althoughdelays were encountered at the FDA, Feridex is back on track andexpected to enter phase two and three clinical trials next month,Goldstein said.

The Squibb deal also involves rights to use core Advanced Magneticstechnology in manufacturing the agents and developing new receptor-directedagents based on proprietary Bristol-Meyers compounds. This technologyinvolves coating an iron-oxide core with a compound in a way thatdirects it to a specific organ system, Goldstein said.

"Everybody thinks of monoclonal antibodies in terms ofdirectable agents or "magic bullets." But it is stillup in the air whether the FDA is going to approve any of those(monoclonal) products. These receptor-directed agents are magicbullets as well," he said.

Of the two agents signed to Squibb, the blood-flow lymphaticagent has the larger market potential. How much use the agentwill get, however, depends on whether clinical trials show thatit can pick up pathology in lymph nodes that are not enlarged,Goldstein said.

"In that answer lies perhaps a five- to 10-fold differencein market size," he said.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.